CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Weight Managemet Raw Retatrutide Powder Peptide Retatrutide1
Pharmaceutical IntermediateRetatrutidePeptide Retatrutide
Xi'an Sase Biotechnology Co., Ltd
Preview:
Product Description Weight Managemet Raw Retatrutide Powder Peptide RetatrutideProduct DescriptionProduct DetailsProduct NameRetatrutideAppearanceWhite PowderCAS2381089-83-2MFN/aMWN/aCharacteristics of Retatrutide (2381089-83-2)Retatrutide (CAS: 2381089-83-2) is a novel, investigational peptide-based therapeutic agent designed for metabolic disorder treatment, particularly targeting obesity and type 2 diabetes. Structurally, it is a triple agonist that simultaneously activates glucose-dependent otropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, offering a multi-hormonal approach to metabolic regulation. This unimolecular peptide is engineered for extended half-life through modifications such as fatty acid acylation, enabling once-weekly subcutaneous administration. Retatrutide exhibits high binding affinity to all three receptors, promoting enhanced glycemic control, appetite suppression, and increased energy expenditure. Preclinical and clinical studies suggest superior efficacy in weight loss compared to single or dual agonists (e.g., or tirzepatide), with mechanisms including slowed gastric emptying, reduced food intake, and improved sensitivity. Its pharmacokinetic profile shows dose-dependent exposure, with minimal accumulation upon repeated dosing. Safety assessments indicate manageable side effects, primarily gastrointestinal (nausea, diarrhea), consistent with incretin-based therapies. Stability studies confirm robustness in lyophilized or solution formulations under refrigerated conditions (2–8°C). Due to its multi-target action, Retatrutide represents a breakthrough in metabolic pharmacology, potentially addressing limitations of existing mono- or dual-agonist therapies.Application&FunctionFunctions and Applications of RetatrutideRetatrutide's triple-hormone agonism enables broad-spectrum metabolic benefits, making it a promising candidate for obesity, type 2 diabetes (T2D), and non-alcoholic steatohepatitis (NASH). By activating GLP-1 receptors, it enhances secretion and suppresses glucagon, lowering blood glucose levels. GIP receptor agonism complements this by improving pancreatic β-cell function and adipocyte lipid metabolism, while glucagon receptor activation stimulates hepatic glucose output and fat oxidation, counteracting obesity-related energy storage. Clinical trials demonstrate significant weight loss (≥15% of body weight) and HbA1c reductions, outperforming GLP-1/GIP dual agonists. Its anorexigenic effects stem from central nervous system actions, reducing cravings and calorie intake. Beyond diabetes and obesity, Retatrutide shows potential for cardiometabolic risk reduction, including improvements in lipid profiles and blood pressure. Ongoing research explores its utility in NASH due to glucagon-mediated lipolysis and anti-fibrotic effects. Formulated for once-weekly injection, it aligns with patient compliance trends in chronic disease management. Regulatory filings are anticipated for obesity/T2D indications, with possible expansion to metabolic syndrome. Compared to competitors, Retatrutide's triple-action mechanism may offer superior efficacy, positioning it as a next-generation therapy for metabolic diseases. Future applications could include polycystic ovary syndrome (PCOS) and Alzheimer's disease, given the role of incretins in neuroprotection and inflammation.Specification
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...